Merck's R&D Chief Says Breadth Gives sac-TMT the Edge in the TROP2 ADC Race
- In an Endpoints interview, Merck R&D head Dean Li argued the company outflanked rivals on next-generation oncology by pushing sac-TMT, its Kelun-licensed TROP2 ADC, into a wide set of indications.
- He pointed to the gynecologic and gastric cancer programs as where the drug has an advantage over competing TROP2 ADCs.
- Context: sac-TMT recently posted a survival benefit in a Phase 3 endometrial cancer trial, which has FDA priority review.
💡 Points Based on public reports
Li is selling breadth as the moat: with TROP2 ADCs converging on lung and breast, Merck is trying to own tumor types where rivals are absent and where Keytruda combinations are natural. It is a sensible hedge against the Keytruda patent cliff, but the claim is an executive's own read, and it only holds if the gynecologic and gastric trials keep delivering.
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program ↗